Mederi draws $18.5M Series B to expand reach of GI treatment devices

Mederi Therapeutics grabbed $18.5 million in new financing to back an expanded commercial push for treatment devices that address gastroesophageal reflux disease and bowel incontinence. Acadia Woods Partners, Respiratory Diagnostics (a Bio-Rad Laboratory subsidiary) and a number of high-net-worth equity investors participated in the Series B financing, which involved preferred stock and venture debt. Greenwich, CT-based Mederi makes and sells medical devices that use radiofrequency energy to treat digestive system-related diseases. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.